Though not exempt from adverse events, azathioprine (AZA) is an inexpensive and effective drug in the induction and maintenance treatment of patients with inflammatory bowel disease. We present the case of a 20-year-old female patient with left-side ulcerative colitis in whom AZA was started at a dose of 1.5 mg/kg/day due to dependence on corticoids (thiopurine methyltransferase activity: 14.9 U/mL). Two weeks after starting treatment she began to report excessive hair loss, resulting in an almost complete loss of scalp hair.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.17235/reed.2021.8175/2021 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Case report: polymorphism and severe azathioprine-induced myelosuppression in a young Chinese female with systematic lupus erythematosus: a case analysis and literature review.
Front Pharmacol
May 2023
Department of Pharmacy, Affiliated Hospital of Zunyi Medical University, Zunyi, China.
Article Synopsis
- Azathioprine (AZA) is used to suppress the immune system in autoimmune diseases but can cause serious side effects like myelosuppression, especially due to genetic differences in metabolism.
- The study highlights a case of a young Chinese woman with specific genetic variations who experienced severe side effects after high doses of AZA for lupus, without proper monitoring of blood cell counts.
- A systematic review of similar cases reveals patterns in blood cell changes associated with genetic variants, aiming to improve clinical management and treatment outcomes for patients on AZA.
Azathioprine-Induced Anagen Effluvium with Myelosuppression.
Skinmed
July 2022
Department of Dermatology, All India Institute of Medical Sciences, Raipur, Chhattisgarh, India.
Article Synopsis
- Anagen effluvium and myelosuppression are uncommon side effects of the medication azathioprine.
- Hair loss from azathioprine occurs more often in transplant patients compared to those who aren't undergoing transplantation.
- The report discusses three patients who experienced hair loss and bone marrow suppression after being treated with azathioprine for skin conditions.
Azathioprine-induced alopecia: a rare adverse event, early marker of myelotoxicity.
Rev Esp Enferm Dig
January 2022
UGC Aparato Digestivo, Hospital de Poniente.
Though not exempt from adverse events, azathioprine (AZA) is an inexpensive and effective drug in the induction and maintenance treatment of patients with inflammatory bowel disease. We present the case of a 20-year-old female patient with left-side ulcerative colitis in whom AZA was started at a dose of 1.5 mg/kg/day due to dependence on corticoids (thiopurine methyltransferase activity: 14.
View Article and Find Full Text PDFThis report highlights azathioprine-induced severe myelosuppression in the patient with NUDT15 minor variant. This case report is particularly instructive because several typical symptoms are the clues to this critical adverse drug reaction.
View Article and Find Full Text PDFAzathioprine-induced Agranulocytosis and Severe Alopecia After Kidney Transplantation Associated With a NUDT15 Polymorphism: A Case Report.
Transplant Proc
December 2018
Division of Nephrology and Rheumatology, National Center for Child Health and Development, Tokyo, Japan. Electronic address:
Background: Azathioprine (AZA) is the drug recommended for the continuation of immunosuppressive treatment after renal transplant in women during pregnancy.
Case Report: A 37-year-old Japanese female developed agranulocytosis and severe alopecia after initiation of AZA (50 mg), used as an alternative to mycophenolate mofetil (MMF, 1000 mg) therapy in anticipation of a planned pregnancy. Within 4 days of the initiation of AZA therapy, the patient developed a high fever, leucopenia, and cranial alopecia.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!